Gestational Weight Gain Below IOM Recommendation Safe in Obesity
By Elana Gotkine HealthDay Reporter
FRIDAY, April 5, 2024 -- Gestational weight gain below the current U.S. Institute of Medicine (IOM) recommendation is safe for pregnancies with obesity, according to a study published online March 28 in The Lancet.
Kari Johansson, Ph.D., from Karolinska Institutet in Stockholm, and colleagues used electronic medical records from the Stockholm-Gotland Perinatal Cohort study to identify pregnancies with obesity among singleton pregnancies that delivered from Jan. 1, 2008, through Dec. 31, 2015. The safety of gestational weight gain below current recommendations or weight loss in pregnancies with obesity was examined.
Data were included for a cohort of 15,760 pregnancies with obesity (74.0, 20.1, and 5.9 percent had class 1, 2, and 3 obesity, respectively), followed for a median of 7.9 years. The researchers found that 13.9, 24.9, and 33.2 percent of pregnancies with class 1, 2, and 3 obesity, respectively, had weight gain below the lower limit of the IOM recommendation (5 kg at term) during pregnancy. Gestational weight gain values below the lower limit of the IOM recommendation or weight loss did not increase risk for the adverse composite outcome in pregnancies with class 1 or 2 obesity. However, weight gain values below the IOM limit or weight loss were associated with a reduced risk for the adverse composite outcome among pregnancies with class 3 obesity (adjusted rate ratio, 0.81 at weight gain z score, −2.4, or 0 kg).
"Gestational weight gain below the current IOM recommendations is likely to be safe in pregnancies with obesity, and might be beneficial for those with class 3 obesity," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.